Show simple item record

dc.contributor.authorPhelan, James
dc.contributor.authorRoche, James J.
dc.identifier.citationPhelan, J., Roche, J.J. (2017). UPLC® method development and validation for the assay of the photolabile drug nifedipine and its trace level degradation products. Irish Chemical News. No.3 June-August, 50-61.en_US
dc.identifier.otherArticles - Life and Physical Sciences AITen_US
dc.description.abstractQuality assurance regulations require that pharmaceutical drugs are highly pure. This is in order to ensure the safety and efficacy of medicines for patients, two fundamental issues of importance in treatment. The safety of a drug is determined by both its pharmacological and toxicological profile as well as impurities present in its dosage form. Impurities may have pharmacological and toxicological effects that outweigh any benefit from the dosage form administration. While the use of a drug to treat a patient is a balance of risk and benefit, impurities in pharmaceuticals provide only risk. Therefore, pharmaceutical companies must characterise what molecules may be present and be able to identify them at low levels or as low as reasonably practicable (ALARP). This involves reducing risk to an acceptable level without disproportionate resource expenditure. Molecule characterisation involves the identification, structural elucidation and quantitative determination of impurities and degradation products. Impurity analysis is therefore a very important field in pharmaceutical characterisation as it allows assurance that a drug is safe and of sufficient quality (Görög, 2000). Due to newer analysis methods becoming available and the need to detect impurities at ever lower levels, ongoing method development and transfer of newer techniques to the quality control laboratory is a reasonable regulatory expectation. However pharmaceutical companies can be innately conservative, with a to change and adaptation to new techniques that can require significant resource investment. Although current techniques may appear adequate, when dealing with impurities that can impact patient safety, in particular genotoxic impurities, this resource allocation is prudent.en_US
dc.publisherThe Institute of Chemistry of Irelanden_US
dc.relation.ispartofIrish Chemical Newsen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland*
dc.subjectDrugs - Toxicologyen_US
dc.titleUPLC® method development and validation for the assay of the photolabile drug nifedipine and its trace level degradation products.en_US
dc.rights.accessOpen Accessen_US
dc.subject.departmentFaculty of Science and Healthen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland